PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Early research reveals new clues to origin of diabetes

Mutant gene protein can derail normal insulin production in animal pancreatic beta cells

2010-10-13
(Press-News.org) ANN ARBOR, Mich. – University of Michigan scientists have identified events inside insulin-producing pancreatic cells that set the stage for a neonatal form of non-autoimmune type 1 diabetes, and may play a role in type 2 diabetes as well. The results point to a potential target for drugs to protect normally functioning proteins essential for producing insulin. A study published online today in the journal PLoS One shows that certain insulin gene mutations involved in neonatal diabetes cause a portion of the proinsulin proteins in the pancreas' beta cells to misfold. Proinsulin proteins are the precursors of insulin, which the body needs to regulate blood sugar levels. Crucially, the misfolded mutant proteins cause normal proinsulin proteins in beta cells to misfold as well, the scientists found in studies of mouse and rat beta cells. "Once the 'good' proinsulin turns 'bad,' it cannot be made into insulin and so the beta cells, and then the whole animal, become insulin deficient. The insulin deficiency causes diabetes and from there, things get worse and worse," says Peter Arvan, M.D., Ph.D., the study's senior author. He directs the Michigan Comprehensive Diabetes Center and is William and Delores Brehm Professor and chief of Metabolism, Endocrinology and Diabetes at the U-M Medical School.

Significance

"We want to see how the mechanism we found in this rare form of neonatal diabetes applies to other forms of diabetes," says Ming Liu, M.D., Ph.D., the study's first author and a research assistant professor of internal medicine at the U-M Medical School.

Diabetes researchers know that protein misfolding in beta cells also occurs on a smaller scale in mice and people without diabetes, and at higher levels in type 2 diabetes, Arvan says. In type 2 diabetes, people develop reduced sensitivity to insulin, causing beta cells to work overtime and eventually fail. In non-autoimmune type 1, diabetes results when genetic mutations cause insufficient production of insulin from pancreatic beta cells.

"In all diabetes, beta cells don't perform to the level needed," says Arvan. "It's possible that the beta cell failure of type 2 diabetes also has a critical protein folding component," he says. "The question is, can you reach a point in ordinary diabetes where misfolding causes the problem we have identified?"

Research details

In lab dish cultures of normal rat and mice beta cells, the scientists introduced single gene mutations known to be involved in various types of neonatal diabetes. They consistently found that misfolding occurred in normal proinsulin protein when mutant proinsulin protein was present. They also observed the same aberrant events in the pancreatic beta cells of Akita mice, a mouse model with the same mutation that occurs in a human family with neonatal diabetes.

Context

Proteins, which are molecules made of amino acids arranged in a certain order determined by genes, normally fold into specific shapes. But sometimes misfolding occurs. Protein folding is a phenomenon that has drawn a lot of recent attention from scientists who believe it plays a role in several common diseases.

Diabetes researchers currently lack a clear picture of why beta cells in the pancreas fail in diabetes. Many researchers look at stress and the stress response from the beta cells' endoplasmic reticulum or ER, a structure that transports materials within the cell. Stress in this structure occurs in diabetes, along with reduced beta cell mass.

Arvan and Liu found in the study that each of the mutations they examined led to ER stress and the ER stress response in beta cells, but that these ER events alone could not block insulin production in normal beta cells and do not appear to be the origin of the insulin deficiency. They hypothesize that protein misfolding events first block insulin production and cause insulin deficiency, leading to diabetes.

What's next

Uncovering the earliest events in the molecular mechanism of the disease may help diabetes researchers discover new therapies, the authors say. New drugs that could emerge would be at least several years away.

"It may be possible to find a way to modulate the environment in the endoplasmic reticulum to let the normal protein fold quickly, before the abnormal protein can act," says Liu.

INFORMATION: Additional authors: Leena Haataja, Jordan Wright, U-M Medical School; Nalinda P. Wickramasinghe, Qing-Xin Hua, Nelson F. Phillips, Michael A. Weiss, Case Western Reserve University; Fabrizio Barbetti, University of Tor Vergata, Rome, Italy.

Funding: National Institutes of Health

Citation: PLoS One, http://dx.plos.org/10.1371/journal.pone.0013333

Resources:
http://www.med.umich.edu/diabetes/brehmcenter/
http://www.med.umich.edu/diabetes/



ELSE PRESS RELEASES FROM THIS DATE:

Global research effort leads to new findings on genes and obesity

2010-10-13
October 10, 2010─(BRONX, NY) ─Two major international studies looking at data from a quarter of a million people around the globe have found a new set of genes associated with body fat distribution and obesity. Researchers at 280 institutions worldwide, including Albert Einstein College of Medicine of Yeshiva University, conducted the studies. The research, published in the October 10 online edition of Nature Genetics, sheds light on the biological processes involved in body fat distribution, possibly leading to new ways of treating obesity. "These studies ...

NFL players with concussions now sidelined longer

2010-10-13
Los Angeles, CA (October 11, 2010) NFL players with concussions now stay away from the game significantly longer than they did in the late 1990s and early 2000s, according to research in Sports Health (owned by American Orthopaedic Society for Sports Medicine and published by SAGE). The mean days lost with concussion increased from 1.92 days during 1996-2001 to 4.73 days during 2002-2007. In an effort to discover whether concussion injury occurrence and treatment had changed, researchers compared those two consecutive six-year periods to determine the circumstances of ...

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

2010-10-13
Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase-III clinical trial confirm. "This is a major step forward in prostate cancer therapeutics," said Dr Johann de Bono from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust in London, who presented the study results at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. "Patients in this Phase-III ...

Fertility concerns of cancer survivors inadequately addressed, study finds

2010-10-13
Many cancer survivors experience changes in sexual function that leave them feeling guilty and a longing for intimacy, Australian researchers told at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. The researchers say that these sexuality and fertility concerns are often not adequately addressed by doctors. Professor Bogda Koczwara from Flinders Medical Centre in Adelaide said that fertility concerns among cancer survivors was a growing problem, due to a combination of improved cancer treatment outcomes in young cancer survivors ...

Re-evaluating the time of your life

2010-10-13
In life, we're told, we must take the good with the bad, and how we view these life events determines our well-being and ability to adjust. But according to Prof. Dov Shmotkin of Tel Aviv University's Department of Psychology, you need more than the right attitude to successfully negotiate the vicissitudes of life. As recently reported in Aging and Mental Health, Prof. Shmotkin's research reveals that people's well-being and their adaptation can be ascertained by their "time trajectory" ― their concept of how they have evolved through their remembered past, currently ...

Sexual issues a major concern for cancer patients taking new targeted drugs

2010-10-13
New drugs that target specific molecular mechanisms of cancer have improved the treatment of cancer patients in recent years, but those benefits may come with a cost to the patient's sex life, researchers have found. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, French researchers reported on one of the few studies to investigate the impact of cancer therapy on the sexual functioning of patients. Dr Yohann Loriot and Dr Thomas Bessede from Institut Gustave Roussy in Villejuif, France and colleagues found that patients taking ...

Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

2010-10-13
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, Dr Vincent Miller from Memorial Sloan-Kettering Cancer Center in New York, USA, reported findings from the LUX-Lung 1 trial of afatinib in 585 patients with lung adenocarcinoma whose cancer had progressed after chemotherapy ...

New Phase II study shows first-line promise of lung cancer drug PF-299

2010-10-13
A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in patients with advanced disease, investigators reported at the 35th Congress of the European Society for Medical Oncology (ESMO). Preliminary results from an ongoing Phase-II trial of the drug PF299804 (PF-299) showed that close to 85% of patients whose cancers harbor mutated forms of the EGFR gene have remained progression-free for at least nine months, reported Dr Tony Mok from the Chinese University of Hong Kong. While some ...

Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer

2010-10-13
An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. Urothelial cancers affect the tissue lining the inner surfaces of the bladder and other parts of the urinary system. In cases of metastatic disease, median survival is approximately 12-15 months and there is a 10-15% chance of prolonging it by the use of standard chemotherapy regimens, particularly in otherwise healthy ...

Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors

2010-10-13
The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells. At the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Marianne Pavel from Charité University in Berlin, Germany reported that everolimus improved progression-free survival by 5.1 months in patients with advanced neuroendocrine tumors. Neuroendocrine tumors are slow-growing malignancies that originate from cells of the body's neuroendocrine ...

LAST 30 PRESS RELEASES:

Researchers awarded $2.5 million grant to increase lung cancer screenings in underserved communities

New trigger proposed for record-smashing 2022 Tonga eruption

Lupus Research Alliance announces Lupus Research Highlights at ACR Convergence 2024

Satellite imagery may help protect coastal forests from climate change

The secrets of baseball's magic mud

Toddlers understand concept of possibility

Small reductions to meat production in wealthier countries may help fight climate change, new analysis concludes

Scientists determine why some patients don’t respond well to wet macular degeneration treatment, show how new experimental drug can bridge gap

Did the world's best-preserved dinosaurs really die in 'Pompeii-type' events?

Not the usual suspects: Novel genetic basis of pest resistance to biotech crops

Jill Tarter to receive Inaugural Tarter Award for Innovation in the search for life beyond earth

Survey finds continued declines in HIV clinician workforce

Researchers home in on tumor vulnerabilities to improve odds of treating glioblastoma

Awareness of lung cancer screening remains low

Hospital COVID-19 burden and adverse event rates

NSF NOIRLab astronomers discover the fastest-feeding black hole in the early universe

Translational science reviews—a new JAMA review

How the keto diet could one day treat autoimmune disorders

Influence of tool corner radius on chip geometrical characteristics of machining Zr-based bulk metallic glass

Megan Huisingh-Scheetz, MD, MPH, of the University of Chicago recognized with AFAR’s Terrie Fox Wetle Rising Star Award in Health Services and Aging Research

Steven N. Austad, PhD, to receive inaugural George M. Martin Lifetime Achievement in Mentoring Award

Jeremy D. Walston, MD, of Johns Hopkins University to receive AFAR 2024 Irving S. Wright Award of Distinction

SwRI receives $23 million in U.S. Air Force contracts to sustain aging aircraft

Insilico Medicine enters into revolving loan facility of up to US$100 Million with HSBC

Security in quantum computing

Noninvasive choroidal vessel analysis via deep learning: A new approach to choroidal optical coherence tomography angiography

National Multiple Sclerosis Society awards $1M to Case Western Reserve University researchers to study new approach to treat the disease

Virginia Tech researchers find menthol restrictions may drive smokers to healthier alternatives

Japanese study reveals the importance of new overtime restrictions on physician’s mental health

Space: A new frontier for exploring stem cell therapy

[Press-News.org] Early research reveals new clues to origin of diabetes
Mutant gene protein can derail normal insulin production in animal pancreatic beta cells